(Q35143947)

6 August 2017

1 reference

title

Toxicity of platinum compounds (English)

1 reference

6 August 2017

1 reference

0 references

2

Hans-Peter Lipp

1 reference

6 August 2017

Jörg Thomas Hartmann

1

1 reference

PubMed ID

12783586

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

1 reference

6 August 2017

4

1 reference

6 August 2017

889-901

1 reference

6 August 2017

6

1 reference

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Oxaliplatin: a review of its use in the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Estimation of glomerular filtration rate in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Diagnosis and treatment of patients with testicular germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

21 January 2018

Cisplatin neurotoxicity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Neurotoxicity secondary to antineoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Ototoxic impact of cisplatin in pediatric oncology patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

21 January 2018

Carboplatin is ototoxic.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Application of the area under the curve of carboplatin in predicting toxicity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Cisplatin and hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Renal dysfunction following high-dose carboplatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Cisplatin-induced vomiting depends on circadian timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Effects of cisplatin on urinary thromboxane B2 excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Platinum organ toxicity and possible prevention in patients with testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Amifostine in clinical oncology: current use and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

Fertility after chemotherapy for testicular germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.6.889

21 January 2018

Identifiers

DOI

10.1517/14656566.4.6.889

1 reference

6 August 2017

1 reference

PubMed ID

12783586